MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Immunohistochemistry or IHC

Often used to diagnose cancer, Immunohistochemistry or IHC is a process by which antibodies are detected in tissue samples by use of a specific antigen or antigens. IHC is also widely used in basic research to understand the distribution and localization of biomarkers in different parts of a tissue (also see “Serum Marker/Blood Test“).

Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.

Journal of Thoracic Disease 2019 April [Link] Rodríguez-Cid JR, García-Acevedo O, Benjamin-Contreras J, Bonilla-Molina D, Flores-Mariñelarena RR, Martínez-Barrera L, Alatorre-Alexander JA, Sanchez-Ríos CP, Flores-Soto MDR, Santillan-Doherty PJ, Peña-Mirabal ES Abstract BACKGROUND: Overexpression of estrogen receptors in malignant pleural mesothelioma has shown an independent relation with a better prognosis of survival, and the use of selective […]

Comments Off on Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.

Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Cytopathology 2019 June 5 [Link] Önder S, Özogul E, Koksal D, Sarinc Ulasli S, Firat P, Emri S Abstract OBJECTIVE: The aim of this study was to investigate the utility of BAP1, GLUT-1 and desmin expression by immunohistochemistry in the discrimination between reactive and malignant mesothelial proliferations. METHODS: A total of 88 biopsies and 30 […]

Comments Off on Diagnostic Value of BAP1, GLUT-1 and Desmin Expression in the Discrimination Between Reactive Mesothelial Proliferation and Malignant Mesothelioma in Tissues and Effusions.

Signet ring cell mesothelioma; A diagnostic challenge

Pathology Research and Practice 2019 May 22 [Link] Wang H, Herath C Abstract Signet ring cell mesothelioma is a rare variant of epithelioid mesothelioma with limited cases published. It has a male predilection and most commonly occurs on pleura; it can also arise in the peritoneal cavity. The signet ring cell morphology can pose a […]

Comments Off on Signet ring cell mesothelioma; A diagnostic challenge

CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.

BMC Cancer 2019 May 28 [Link] Kettunen E, Savukoski S, Salmenkivi K, Böhling T, Vanhala E, Kuosma E, Anttila S, Wolff H Abstract BACKGROUND: Deletion of the CDKN2A locus is centrally involved in the development of several malignancies. In malignant pleural mesothelioma (MPM), it is one of the most frequently reported genomic alteration. MPM is […]

Comments Off on CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.

Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma.

Histopathology 2019 April 8 [Link] Hamasaki M, Kinoshita Y, Yoshimura M, Matsumoto S, Kamei T, Hiroshima K, Sato A, Tsujimura T, Kawahara K, Nabeshima K Abstract Malignant pleural mesothelioma (MPM) is an aggressive neoplasm with poor prognosis. Diagnosis includes verification of mesothelial origin and discrimination of MPM from reactive mesothelial hyperplasia (RMH) or reactive mesothelial […]

Comments Off on Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma.

The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.

Pathology Oncology Research 2019 April 2 [Link] Oguh-Olayinka L, Agarwal V, Ranatunge D, Campbell A, Laufer S, Cawkwell L, Lind MJ Abstract Advanced malignant pleural mesothelioma (MPM) has an extremely poor prognosis with limited chemotherapy options, therefore the identification of new therapeutic targets would aid in disease management. Arachidonic acid is metabolised by cyclooxygenase and […]

Comments Off on The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma.

Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.

Liang Y, Zheng G, Yin W, Song H, Li C, Tian L, Yang D Abstract OBJECTIVE: The aim of our study was to investigate the expression of EGFR and PTEN in tissues and measure the serum platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) to evaluate the prognostic factors of patients with epithelioid malignant peritoneal mesothelioma […]

Comments Off on Significance of EGFR and PTEN Expression and PLR and NLR for Predicting the Prognosis of Epithelioid Malignant Peritoneal Mesothelioma.

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.

Molecular Biology Reports 2019 March 6 [Link] Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven […]

Comments Off on Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.

About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.

Journal of Immunoassay & Immunochemistry 2019 February 27 [Link] Mlika M, Zorgati M, BenKhelil M, Mezni FE Abstract BACKGROUND: The positive diagnosis of MPM is based on morphologic features coupled with immunohistochemical findings. Many antibodies have been published especially in order to differentiate between malignant tumors and atypical mesothelial hyperplasia. BAP-1 is a BRCA1-binding protein […]

Comments Off on About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.

Human Pathology 2019 February 19 [Link] Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G Abstract Malignant mesothelioma (MM) is an aggressive neoplasm with poor prognosis. The Dako PD-L1 22C3 and 28-8 pharmDx assays are approved by the US Food and Drug Administration (FDA) as companion and complementary diagnostics for the anti-PD-1 […]

Comments Off on Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.